DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19—A Therapeutic Approach of Choice in Type 2 Diabetic Patients?

Since the outbreak of SARS-CoV-2 virus more than 12,500,000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-...

Descripción completa

Detalles Bibliográficos
Autores principales: Smelcerovic, Andrija, Kocic, Gordana, Gajic, Mihajlo, Tomovic, Katarina, Djordjevic, Vukica, Stankovic-Djordjevic, Dobrila, Anderluh, Marko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419672/
https://www.ncbi.nlm.nih.gov/pubmed/32848788
http://dx.doi.org/10.3389/fphar.2020.01185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419672/
https://www.ncbi.nlm.nih.gov/pubmed/32848788
http://dx.doi.org/10.3389/fphar.2020.01185

Ejemplares similares